What makes a drug a blockbuster — or a cautionary tale?
Though Aduhelm's last rights had arguably already been read before Biogen retired the drug, it's worth looking back on the rise and fall of such a controversially approved drug:
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hey there. Today, we talk about how biomanufacturing is getting a huge boost in North Carolina, study a new potential root for autoimmune disease in women, and more.
What's Your Reaction?
